Predictive Value of Systemic Inflammatory Markers in the Prognosis of Prostate Cancer with Variant Histology
Urology Journal,
Vol. 22 No. 04 (2025),
8 October 2025
,
Page 187-192
https://doi.org/10.22037/uj.v22i.8378
Abstract
Objective: This study aimed to investigate the potential role of systemic inflammatory markers in the management of Prostate Cancer (PCA) with variant pathology.
Materials and Methods: A retrospective analysis was conducted on 302 patients who underwent radical prostatectomy between 2014 and 2023. After applying exclusion criteria, 279 patients were included: 207 with adenocarcinoma and 72 with variant pathologies. Systemic inflammatory markers such as Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), Systemic Immune-Inflammation Index (SII), and Systemic Inflammation Response Index (SIRI) were compared between the groups.
Results: Patients in the variant group were significantly older (p = 0.005). The frequencies of lymphovascular invasion (LVI), perineural invasion (PNI), and positive surgical margins (SM) were significantly higher in the variant histology group (p < 0.001, p = 0.014, and p < 0.001, respectively), as were ISUP grades (p < 0.001). Pretreatment PSA values were also significantly higher in the variant group (p < 0.001), as was the rate of subsequent radiotherapy (p < 0.001). However, no significant differences were found in NLR, PLR, SIRI, or SII values between the groups. Recurrence rates were significantly higher in the variant group (p < 0.05), but overall mortality did not differ.
Conclusion: Systemic inflammation markers have limited value in predicting prognosis among patients with variant PCA. This highlights the complex role of inflammation in cancer progression and underscores the need for further research to identify more specific biomarkers for different PCA variants.
- prostate cancer
- Systemic Immun Inflammation Index
- SII
- histological variant
How to Cite
References
Gandaglia G, Leni R, Bray, F, et al.Epidemiology and Prevention of Prostate Cancer. Eur Urol Oncol. 2021;4:877–92.
Basiri A, Eshrati B, Zarehoroki A, et al. Incidence, Gleason Score and Ethnicity Pattern of Prostate Cancer in the Multi-ethnicity Country of Iran During 2008-2010. Urol J. 2020;17:602-06.
Sung H, Ferlay J, Siegel RL, et al. (Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin.2021;1:209–49.
Cooperberg MR, Pasta DJ., Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173:1938–42.
Zhou J, Ding J, Qi J. Comparison of Typical Prostate Adenocarcinoma and Rare Histological Variant Prostate Cancer Showed Different Characteristics and Prognosis: A Surveillance, Epidemiology, and End Results Database Analysis. Eur. Urol. 2022;82:152–55.
Surintrspanont J, Zhou M. Prostate Pathology: What is New in the 2022 WHO Classification of Urinary and Male Genital Tumors? Pathologica, 2022;115: 41–56.
Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014;110:1409–12.
Catalano M, Roviello G, Santi R, et al. Inflammation in Urological Malignancies: The Silent Killer. Int. J. Mol. Sci. 2023;24:866.
Bekes EM, Schweighofer B, Kupriyanova TA, et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol. 2011;179: 1455–70.
Hanna RN, Cekic C, Sag D, et al. (2015). Patrolling monocytes control tumor metastasis to the lung. Science. 2015;350; 985–90.
Coffelt SB, Kersten K, Doornebal CW, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.Nature, 2015;522:345–48.
Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature. 2015;528:413–17.
Li N. Platelets in cancer metastasis: To help the “villain” to do evil. Int J Cancer. 2016;138:2078–87.
Lucotti S, Cerutti C, Soyer M, et al. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. J Clin Invest.2019;129:1845–62.
Tyagi T, Jain K, Yarovinsky TO, et al. Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. J Exp Med;2023;220.
Cavassani KA, Meza RJ, Habiel DM, et al. Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells. Cancer Med. 2018;7: 4639–49.
Zhang Y, Liu F, Wang Y, et al. Evidence of the Prognostic Value of Pretreatment Systemic Inflammation Response Index in Cancer Patients: A Pooled Analysis of 19 Cohort Studies.Dis. Markers. 2020:8854267.
Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18:360.
Sfanos KS, De Marzo AM. (2012). Prostate cancer and inflammation: the evidence. Histopathology, 2012;60:199–215.
Peng H, Luo X. (2019). Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis. Cancer Cell Int . 2019;19:70.
Rajwa P, Schuettfort VM, D’Andrea D, et al. Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. Urol Oncol. 2021;39:785.e19-785.e27.
Lolli C, Caffo O, Scarpi E, et al.Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Front Pharmacol. 2016;7:376.
Wang Q, Zhu S.-R., Huang X.-P, Liu X.-Q, Liu J.-B, Tian, G. Prognostic value of systemic immune-inflammation index in patients with urinary system cancers: a meta-analysis. Eur Rev Med Pharmacol Sci.2021;25:1302-10
Man Y.-N, Chen Y.-F. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castrationresistant prostate cancer patients treated with first-line docetaxel. Int. Urol. Nephrol. 2019;51:2189–99.
Bailey-Whyte M, Minas TZ, Dorsey TH, Smith CJ, Loffredo CA, Ambs S. Systemic Inflammation Indices and Association with Prostate Cancer Survival in a Diverse Patient Cohort. Cancers. 2023;15:1869.
Arı E, Köseoğlu H, Eroğlu T. Predictive value of SIRI and SII for metastases in RCC: a prospective clinical study. BMC Urol. 2024;24:14.
Huang Y, Gao Y, Wu Y, Lin H. Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis. Cancer Cell Int. 2020;20:499.
Porter LH, Lawrence, MG, Ilic D, et al. Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. Eur. Urol. 2017;72:492–95.
Khandia R, Munjal A. (2020). Interplay between inflammation and cancer. Adv. Protein Chem. Struct. Biol. 2020;119:199–245.
- Abstract Viewed: 581 times
- 8378/pdf Downloaded: 172 times